Health AI Central
Peer-Reviewed Publication
JMIR Res Protoc2023;12e48740.November 16, 2023Journal Article

Assessing the Efficacy and Safety of a Digital Therapeutic for Symptoms of Depression in Adolescents: Protocol for a Randomized Controlled Trial.

Daniella J Furman1,2, Shana A Hall1,2, Claudia Avina1, Vera N Kulikov1, Jessica I Lake1,2, Aarthi Padmanabhan1,2
1Limbix Health, Inc, San Francisco, CA, United States.
2Big Health, Inc, San Francisco, CA, United States.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Depression is a serious, prevalent, recurrent, and undertreated disorder in adolescents. Low levels of treatment seeking and treatment adherence in this age group, combined with a growing national crisis in access to mental health care, have increased efforts to identify effective treatment alternatives for this demographic. Digital health interventions for mental illness can provide c…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.